State of Michigan Retirement System Trims Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Q1 beat and raised guidance: Thermo Fisher reported adjusted EPS of $5.44 (vs. $5.25 consensus) and revenue of $11.01B (up ~6.2% y/y), and set FY2026 EPS guidance of $24.64–$25.12.
• Institutional positioning: The State of Michigan trimmed its stake by 3.6% to 98,410 shares (worth ~$57.0M), while roughly 89.23% of TMO is held by hedge funds and other institutions.
• Dividend bump and insider activity: Thermo Fisher raised its quarterly dividend to $0.47 (annualized $1.88, yield ~0.4%), and CEO Marc N. Casper sold 5,000 shares (~$2.56M) in recent filings.

State of Michigan Retirement System lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,410 shares of the medical research company's stock after selling 3,700 shares during the period. State of Michigan Retirement System's holdings in Thermo Fisher Scientific were worth $57,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of TMO. Wellington Management Group LLP lifted its stake in shares of Thermo Fisher Scientific by 88.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company's stock worth $1,309,292,000 after acquiring an additional 1,270,191 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Thermo Fisher Scientific by 54.7% in the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company's stock worth $1,732,422,000 after purchasing an additional 1,262,967 shares during the period. Franklin Resources Inc. lifted its position in shares of Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company's stock worth $2,874,069,000 after purchasing an additional 1,028,125 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company's stock valued at $720,576,000 after purchasing an additional 825,649 shares during the period. Finally, Capital World Investors grew its holdings in shares of Thermo Fisher Scientific by 7.4% in the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company's stock worth $4,988,132,000 after purchasing an additional 706,572 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Thermo Fisher Scientific Trading Down 0.1%

NYSE:TMO opened at $469.27 on Monday. The firm has a 50-day simple moving average of $499.11 and a 200-day simple moving average of $549.62. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The firm has a market cap of $174.39 billion, a P/E ratio of 25.80, a P/E/G ratio of 2.33 and a beta of 0.97. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company's quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 24.83 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on TMO shares. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a report on Friday. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday. TD Cowen lowered their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a report on Friday, January 30th. UBS Group reissued a "neutral" rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Evercore reaffirmed an "outperform" rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Buy" and an average price target of $625.55.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.